Effect of combined treatment with aripiprazole and antidepressants on the MK-801-induced deficits in recognition memory in novel recognition test and on the release of monoamines in the rat frontal cortex.

Behavioural Brain Research
Marta HeretaZofia Rogóż

Abstract

According to preclinical and clinical studies, the antidepressant-induced increase in the activity of atypical antipsychotics may efficiently improve the treatment of negative and some cognitive symptoms of schizophrenia. In the present study, we aimed to evaluate the effects of the antidepressants escitalopram and mirtazapine and the atypical antipsychotic drug aripiprazole, administered separately or in combination, on the MK-801-induced deficits in the recognition memory test and on the extracellular levels of monoamines and their metabolites in the rat frontal cortex. Based on the results of the behavioral tests, co-treatment with an ineffective dose of aripiprazole (0.1 mg/kg) and escitalopram (2.5 and 5 mg/kg) or mirtazapine (5 mg/kg) abolished the deficits evoked by MK-801 in the novel object recognition test, and those effects were blocked by the 5-HT1A receptor antagonist (WAY 100,635) or the dopamine D1 receptor antagonist (SCH 23,390). Moreover, co-treatment with aripiprazole (0.3 mg/kg) and escitalopram (5 mg/kg) significantly increased the levels of noradrenaline and serotonin, decreased the level of its metabolite, and did not alter level of dopamine, but decreased the levels of its metabolites. In addition, co-tr...Continue Reading

References

Oct 15, 1984·European Journal of Pharmacology·J E Freedman, G K Aghajanian
Jun 3, 1996·European Journal of Pharmacology·K WedzonyK Gołembiowska
Apr 1, 1997·Journal of Clinical Psychopharmacology·L P Delbressine, R M Vos
Feb 19, 2002·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Junji IchikawaHerbert Y Meltzer
Jun 14, 2002·European Journal of Pharmacology·Shaun JordanC Anthony Altar
Jun 5, 2003·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·David A ShapiroRichard Mailman
Aug 7, 2003·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Rocco ZoccaliEdoardo Spina
Dec 4, 2003·Progress in Neuro-psychopharmacology & Biological Psychiatry·Mark A Geyer, Bart Ellenbroek
Jan 8, 2004·European Journal of Pharmacology·Shaun JordanC Anthony Altar
May 18, 2004·Brain Research Bulletin·Kazuhiko NakayamaHisatoshi Katsu
Jun 29, 2004·Clinical Therapeutics·Anthony DeLeonM Lynn Crismon
Nov 9, 2004·Schizophrenia Research·Keith H NuechterleinRobert K Heaton
Jul 19, 2005·Neuroscience Letters·Alessandro ZocchiChristian A Heidbreder
Nov 25, 2005·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Llorenç Díaz-MataixFrancesc Artigas
Nov 1, 2001·Expert Review of Neurotherapeutics·E Spina, M G Scordo
Dec 19, 2013·Current Pharmaceutical Design·Lakshmi RajagopalHerbert Y Meltzer

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here